大麻使用后尿液中的 Δ9 - 四甲基可纳比诺和代谢物度:系统性审查
Danielle McCartney1, Christopher Irwin2, Jonathon C Arnold3
1Sydney Pharmacy School, The University of Sydney, NSW, Australia.
Pharmacological research
|February 18, 2026
概括
大麻使用模式显著影响尿液药物测试结果. 低剂量和偶尔使用可以超过工作场所的门,而大量使用者可能在戒烟后数周测试阳性.
科学领域:
- 法医毒理学 法医毒理学
- 药理学 药理学是指药理学的学科.
- 大麻素科学 大麻素科学
背景情况:
- 尿液中药物检测通常通过检测11-nor-9-carboxy-Δ9-tetrahydrocannabinol (11-COOH-THC) 来识别大麻使用情况.
- 不同的当局实施不同的度值,以获得阳性测试结果.
- 了解大麻使用模式如何影响代谢物度对于解释测试结果至关重要.
研究的目的:
- 系统地审查尿液中 Δ9-四大麻素 (THC) 和其代谢物度.
- 分析不同大麻管理和使用模式对这些度的影响.
- 在工作场所和体育运动中使用的常见尿液检测门.
主要方法:
- 对涉及大麻管理和用户数据的92项符合条件的研究进行系统审查.
- 从急性和重复剂量研究中合成尿中的THC和11-COOH-THC度.
- 在积极使用和长期戒断期间分析度.
主要成果:
- 低单次或重复剂量的THC,特别是口服的THC,可以超过标准的工作场所值 (15ng/mL).
- 每周或每天使用大麻的人可能在停止使用后的几周内保持在工作场所门以上.
- 适度的THC剂量和每周使用可以超过WADA决定限值 (180ng/mL),重度使用者检测阳性时间更长.
结论:
- 大麻使用模式显著影响尿液中的11-COOH-THC度.
- 目前的工作场所和体育测试值可能会被各种使用模式所超越,包括低剂量和偶尔使用.
- 决策者和个人可以从这种综合中获益,以便明智地选择值和风险评估.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
810
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
810
Drug Concentrations: Measurements
1.2K
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
1.2K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
945
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
945
Measurement of Bioavailability: Pharmacokinetic Methods
311
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
311
Therapeutic Drug Monitoring: Drug Analysis Methods
226
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
226
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
236
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
236


